Liquid biopsy has emerged as a promising non-invasive method for detecting and monitoring hematologic malignancies through the analysis of circulating tumor DNA (ctDNA) and other biomarkers in the blood. While the technique has shown potential for improving diagnosis, prognosis, minimal residual disease detection, therapeutic monitoring, and research in hematologic malignancies, there are still challenges that must be addressed, including improving sensitivity and specificity, optimizing mutation detection, and reducing costs. With continued advances, liquid biopsy has the potential to revolutionize the way hematologic malignancies are diagnosed and treated.